| Autor: |
Hafizi R; Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland., Imeri F; Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland., Wenger RH; Institute of Physiology, University of Zürich, CH-8057 Zürich, Switzerland., Huwiler A; Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland. |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 31; Vol. 22 (17). Date of Electronic Publication: 2021 Aug 31. |
| DOI: |
10.3390/ijms22179467 |
| Abstrakt: |
Erythropoietin (Epo) is the critical hormone for erythropoiesis. In adults, Epo is mainly produced by a subset of interstitial fibroblasts in the kidney, with minor amounts being produced in the liver and the brain. In this study, we used the immortalized renal interstitial fibroblast cell line FAIK F3-5 to investigate the ability of the bioactive sphingolipid sphingosine 1-phosphate (S1P) to stimulate Epo production and to reveal the mechanism involved. Stimulation of cells with exogenous S1P under normoxic conditions (21% O 2 ) led to a dose-dependent increase in Epo mRNA and protein levels and subsequent release of Epo into the medium. S1P also enhanced the stabilization of HIF-2α, a key transcription factor for Epo expression. S1P-stimulated Epo mRNA and protein expression was abolished by HIF-2α mRNA knockdown or by the HIF-2 inhibitor compound 2. Furthermore, the approved S1P receptor modulator FTY720, and its active form FTY720-phosphate, both exerted a similar effect on Epo expression as S1P. The effect of S1P on Epo was antagonized by the selective S1P 1 and S1P 3 antagonists NIBR-0213 and TY-52156, but not by the S1P 2 antagonist JTE-013. Moreover, inhibitors of the classical MAPK/ERK, the p38-MAPK, and inhibitors of protein kinase (PK) C and D all blocked the effect of S1P on Epo expression. Finally, the S1P and FTY720 effects were recapitulated in the Epo-producing human neuroblastoma cell line Kelly, suggesting that S1P receptor-dependent Epo synthesis is of general relevance and not species-specific. In summary, these data suggest that, in renal interstitial fibroblasts, which are the primary source of plasma Epo, S1P 1 and 3 receptor activation upregulates Epo under normoxic conditions. This may have a therapeutic impact on disease situations such as chronic kidney disease, where Epo production is impaired, causing anemia, but it may also have therapeutic value as Epo can mediate additional tissue-protective effects in various organs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
